Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
117.25 USD | +4.75% | +4.29% | +2.90% |
15.01. | Goldman belässt Biontech auf 'Buy' - Ziel 137 Dollar | DP |
14.01. | BioNTech SE Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 09:00 AM |
Zu einer Liste hinzufügen 0 ausgewählt | Umsatz | Nettogewinn | Umsatzrendite | ROE | ROA | Verschuldungsgrad | |
---|---|---|---|---|---|---|---|
3 971 505 823,63 | +24,36% | +18,08% | 4.62x | 4.02x | -13.1x | ||
9 869 200 000,00 | +36,68% | +44,33% | 22.99x | 17.71x | -2.46x | ||
13 117 200 000,00 | +30,14% | +39,08% | 20.74x | 16.2x | -1.6x | ||
1 217 670 819,47 | -23,26% | -33,51% | -8.54x | -7.69x | 10.14x | ||
2 458 779 000,00 | -35,86% | -49,12% | -22.26x | -14.47x | 2.05x | ||
5 525 381 027,26 | +26,50% | +29,43% | 18.99x | 15.45x | -0.64x | ||
1 887 100 000,00 | +13,23% | +13,30% | 12.68x | 8.89x | -5.76x | ||
2 296 847 376,90 | +26,42% | +32,30% | 14.78x | 13.31x | -5.01x | ||
305 208 000,00 | -245,59% | -232,51% | - | -50.2x | -0.8x | ||
1 243 336 000,00 | -43,11% | -21,54% | -86.15x | -1.86x | 1.96x | ||
1 830 208 000,00 | +11,35% | +9,34% | 8.74x | 6.91x | -5.06x | ||
2 333 139 980,82 | +19,96% | +24,97% | 9.02x | 6.41x | -0.78x | ||
277 368 968,39 | -180,51% | -170,79% | -818.43x | -50.27x | -0.33x | ||
156 178 000,06 | -12,22% | -37,48% | -3.46x | -2.93x | 11.91x | ||
47 792 383,07 | -205,30% | -166,94% | -58.43x | - | 2.98x | ||
619 949 732,91 | +44,81% | +45,26% | 55.36x | 27.64x | 0.65x | ||
Durchschnitt | 2’947’304’069.53 | -32.02% | -28.49% | -55.29x | -0.73x | -0.37x | |
Gewichteter Durchschnitt nach Marktkapitalisierung | 6’327’195’785.11 | +0.81% | +4.27% | -7.89x | 6.42x | -1.00x |
- Börse
- Aktien
- A2PSR2 Aktie
- Sektor BioNTech SE
- Finanzielle Vergleiche
MarketScreener is also available in this country: United States.
Switch edition